By Sarah Roden It’s been a busy week in the pharmaceutical industry with new data emerging on trial drugs and M&A between drug …
By Sarah Roden Valeant Pharmaceuticals (NYSE:VRX) beat out Endo International in a battle to take over Salix Pharmaceuticals (NASDAQ:SLXP) in a deal valued …
A handful of bio-pharmaceutical stocks are announcing their financial results for the final quarter of 2014 this week. What should investors watch for?
This week was a busy one for biopharma BD teams. Finallized on Sunday, Valeant (VRX) will pay $158 per share for Salix Pharmaceuticals (SLXP) in an all-cash …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that they have entered into a definitive agreement under which Valeant will acquire all …
(BUSINESS WIRE)–Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) (“Salix” or the “Company”) today announced the promotion of William P.
(BUSINESS WIRE)–Pharming Group NV (EURONEXT: PHARM) and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the first patient was treated in their Phase 2 …
In a research report published today, Cantor analyst Irina Rivkind reiterated a Buy rating on Salix Pharmaceuticals (NASDAQ:SLXP) and raised her price target to …
I wrote about generic and specialty drug company Actavis plc (NYSE:ACT) a while back detailing the rumored love triangle between them, Allergan (NYSE:AGN), …
In a research report issued today, Cantor analyst Irina Rivkind reiterated a Buy rating on Salix Pharmaceuticals (NASDAQ:SLXP), but reduced her price target to $127 …
